Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
1984-6-22
|
pubmed:language |
ita
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:issn |
0374-9320
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
24
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
145-53
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:6145083-Acetylcholine,
pubmed-meshheading:6145083-Antiparkinson Agents,
pubmed-meshheading:6145083-Antipsychotic Agents,
pubmed-meshheading:6145083-Basal Ganglia Diseases,
pubmed-meshheading:6145083-Brain,
pubmed-meshheading:6145083-Dopamine,
pubmed-meshheading:6145083-Dyskinesia, Drug-Induced,
pubmed-meshheading:6145083-Humans,
pubmed-meshheading:6145083-Receptors, Dopamine
|
pubmed:articleTitle |
[Current status of our knowledge of the neurotropic side effects of neuroleptic drugs].
|
pubmed:publicationType |
Journal Article,
English Abstract,
Review
|